Handelsavisen
prelaunch
Companies ›Healthcare ›ALCOX.PA
AL
ALCOX.PA — Euronext Paris Pharmaceuticals

Nicox SA

€0,40
Open in Charts → Attach watcher ⌖
— —
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Nicox SA is a biotechnology company focused on the development and commercialization of pharmaceutical products, primarily in the ophthalmology and urology therapeutic areas.

Business. Nicox SA (ALCOX.PA) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target1,50

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
1,50
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
1 analysts · indicative
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ALCOX.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ALCOX.PA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Nicox SA (ALCOX.PA) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Nicox SA has a total revenue of €1.8 million, with 88.13 million shares outstanding, both basic and diluted, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    Profitability metrics are not available in the current dataset, and no industry-specific preferred metrics are provided for comparison. Without access to profitability ratios such as net margin or ROIC, it is not possible to assess Nicox’s performance relative to industry medians.

    Nicox’s revenue is not segmented by geographic region or product line in the available data, so it is not possible to determine the geographic or segment concentration of its revenue.

    The company’s growth trajectory is unclear due to the lack of historical revenue data and forward-looking guidance. Analysts have provided a mean price target of €1.50, with a median and high target also at €1.50, and a mean recommendation of 2.00 (indicating a "Hold").

    The primary risk factor is the inability to assess liquidity risk due to missing balance-sheet data. Additionally, the absence of detailed risk disclosures in source documents limits the ability to evaluate other potential risks.

    No recent events, such as filings or transcripts, are available in the current dataset to provide insight into the company’s recent developments.

    Key takeaways
    • Nicox SA has a total revenue of €1.8 million and 88.13 million shares outstanding, with no immediate dilution pressure.
    • Analysts have assigned a mean price target of €1.50 and a "Hold" recommendation.
    • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
    • No profitability metrics or industry comparisons are available in the current dataset.
    • No recent events or filings are available to inform the company’s near-term outlook.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    ANNUALFiled 2026-04-30
    FY 2026 · Full-year highlights

    Revenue €16.8M, +113,4% YoY; Operating income +33,8% YoY.

    Revenue€16.8M+113,4 % YoY
    Operating income-€15.5M+33,8 % YoY
    Net income-€2.4M+89,2 % YoY
    Free cash flow—
    EPS—
    Operating cash flow—
    Financials
    Income statement
    Revenue€16.8M
    Gross profit—
    Operating income-€15.5M
    Net income-€2.4M
    Margins
    Gross margin—
    Operating margin-92.7%
    Net margin-14.4%
    FCF margin—
    Balance sheet
    Total assets€10.4M
    Total liabilities€4.4M
    Total equity€6.0M
    Cash & equivalents€4.1M
    Long-term debt€403.7k
    P&L flow · revenue → net income
    Revenue €16.8MOperating costs €32.3MNet income €2.4M
    Highlights
    • ▍Revenue €16.8M, +113,4% YoY
    • ▍Operating income +33,8% YoY
    • ▍Net income +89,2% YoY
    • ▍Net margin -14.4%

    Valuation FY

    Market price
    €0,40
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,13
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-12 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate0,13
    Revenue—no estimate—no estimate20,0M EUR
    Operating income—no estimate—no estimate11,0M EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target€1,50 · Median €1,50
    Low €1,50High €1,50
    Operating income · consensus11,0M EUR
    EPS surprise
    −123,1 %
    reported vs consensus · miss
    Revenue surprise
    −16,1 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low€1,50
    Mean€1,50
    Median€1,50
    High€1,50
    Spot€0,40
    +272.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Nicox SA Market data — financials · 2026-05-27
    • Nicox SA Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ALCOX.PACanonical
    Euronext Paris · EUR

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-04-30 06:32 UTCEARNINGSAnnual results — FY 2026 Revenue EUR 16.8M · Net EUR -2.4M
    2025-04-30 06:30 UTCEARNINGSQuarterly results — Q1 2025
    2025-04-30 06:30 UTCEARNINGSAnnual results — FY 2025 Revenue EUR 7.9M · Net EUR -22.4M
    2024-07-18 08:47 UTCEARNINGSQuarterly results — Q2 2024
    2024-04-23 08:47 UTCEARNINGSQuarterly results — Q1 2024 Revenue EUR 1.8M
    2024-04-22 08:15 UTCEARNINGSAnnual results — FY 2024 Revenue EUR 6.9M · Net EUR -20.9M
    2023-03-20 06:30 UTCEARNINGSAnnual results — FY 2023 Revenue EUR 5.5M · Net EUR -31.3M
    2022-01-21 14:51 UTCEARNINGSAnnual results — FY 2022 Revenue EUR 7.2M · Net EUR -43.8M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage